Henry Schein (HSIC) came out with quarterly earnings of $1.1 per share, missing the Zacks Consensus Estimate of $1.18 per share. This compares to earnings of $1.23 per share a year ago.
Henry Schein remains a "Buy" as its valuation is attractive relative to peers, despite recent underperformance versus the S&P 500. Financial results have been mixed, but management's 2025 guidance suggests revenue and earnings growth are likely ahead. Ongoing acquisitions and a strategic $250 million investment from KKR support long-term growth and capital allocation flexibility.
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HSIC eyes modest Q2 gains, with dental, medical and specialty segments showing signs of steady momentum.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors are optimistic about HSIC, owing to the strong Henry Schein One performance. However, macro headwinds and fierce competition pose challenges.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.